A study conducted by the University of Oxford in the UK showed a correlation between Novo Nordisk's diabetes treatment drug, Ozempic, and a reduction in the risk of dementia.

July 12, 2024 19:59 JST (excerpts)

A study conducted by the University of Oxford in the UK has shown a correlation between Novo Nordisk's diabetes treatment drug, Ozempic, and a reduction in the incidence of symptoms such as dementia. This result has raised expectations for the secondary effects of Ozempic.
According to the study, patients who took Ozempic for one year had a 48% lower risk of dementia compared to patients who took the previously available drug, sitagliptin. They also had a lower risk of developing cognitive impairment compared to patients who took either sitagliptin or the previously available drug, glipizide.